Skip to content

Study · Non-randomized trial · n = 8 · 1988

4 results

A bronchodilator action of glucagon.

Sherman MS, Lazar EJ, Eichacker P

The Journal of allergy and clinical immunology1 May 1988Cited by 21 (Europe PMC)

PMID3372910 (opens in a new tab)DOI10.1016/0091-6749(88)90949-9 (opens in a new tab)PepBankPUB-03372910
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with asthma, glucagon increased FEV1 compared with placebo (17.5% versus -2.4%, p less than 0.02).

    In plain wordsIn patients with asthma, glucagon increased the volume exhaled in one second compared with placebo.

    Peptide
    Glucagon
    Outcome
    IncreaseFEV1
    Study

    n = 8

    Comparator
    Saline placebo
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    2 units · intravenousAs given in this study (human).

    Measurements

    FEV1 change
    17.5%
    glucagon
    SEM
    5.5%
    glucagon
    FEV1 change
    −2.4%
    placebo
    SEM
    2.9%
    placebo
    p
    < 0.02
    between groups

    Source sentences

    Summary
    Glucagon significantly improved the FEV1 (17.5% +/- 5.5 SEM) and the peak expiratory flow rate (14.2% +/- 4.9), compared to placebo (-2.4% +/- 2.9, p less than 0.02; 4.5% +/- 4.1, p less than 0.25, respectively).
    2 context sentences
    Summary · context
    We evaluated the effect of glucagon on eight patients with asthma.
    Summary · context
    After withholding bronchodilators for 12 hours, patients received either 2 units of intravenous glucagon or 2 ml of saline after a double-blind crossover protocol.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with asthma, peak expiratory flow increased 14.2% with glucagon versus 4.5% with placebo (p less than 0.25).

    In plain wordsIn patients with asthma, peak airflow increased more with glucagon than placebo, with p less than 0.25.

    Peptide
    Glucagon
    Outcome
    IncreasePeak expiratory flow rate
    Study

    n = 8

    Comparator
    Saline placebo
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    2 units · intravenousAs given in this study (human).

    Measurements

    Peak flow change
    14.2%
    glucagon
    SEM
    4.9%
    glucagon
    Peak flow change
    4.5%
    placebo
    SEM
    4.1%
    placebo
    p
    < 0.25
    between groups

    Source sentences

    Summary
    Glucagon significantly improved the FEV1 (17.5% +/- 5.5 SEM) and the peak expiratory flow rate (14.2% +/- 4.9), compared to placebo (-2.4% +/- 2.9, p less than 0.02; 4.5% +/- 4.1, p less than 0.25, respectively).
    2 context sentences
    Summary · context
    We evaluated the effect of glucagon on eight patients with asthma.
    Summary · context
    After withholding bronchodilators for 12 hours, patients received either 2 units of intravenous glucagon or 2 ml of saline after a double-blind crossover protocol.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with asthma, seven had an excellent glucagon response, measuring 40% to 105% of their response to inhaled isoproterenol.

    In plain wordsIn patients with asthma, seven had excellent glucagon responses, measuring 40% to 105% of their responses to inhaled isoproterenol.

    Peptide
    Glucagon
    Outcome
    IncreaseExcellent bronchodilator response
    Study

    n: not reported in source

    Comparator
    Inhaled isoproterenol
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    2 units · intravenousAs given in this study (human).

    Measurements

    Responders
    7 patients
    excellent response
    Relative response
    40 to 105%
    inhaled isoproterenol response

    Source sentences

    Summary
    Seven patients had an excellent response to glucagon (40% to 105% of the response to inhaled isoproterenol), but four patients had no significant response.
    2 context sentences
    Summary · context
    We evaluated the effect of glucagon on eight patients with asthma.
    Summary · context
    After withholding bronchodilators for 12 hours, patients received either 2 units of intravenous glucagon or 2 ml of saline after a double-blind crossover protocol.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with asthma, four had no significant response to glucagon.

    In plain wordsIn patients with asthma, four had no significant response to glucagon.

    Peptide
    Glucagon
    Outcome
    No significant changeNo significant bronchodilator response
    Study

    n: not reported in source

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    2 units · intravenousAs given in this study (human).

    Measurements

    Nonresponders
    4 patients
    glucagon

    Source sentences

    Summary
    Seven patients had an excellent response to glucagon (40% to 105% of the response to inhaled isoproterenol), but four patients had no significant response.
    2 context sentences
    Summary · context
    We evaluated the effect of glucagon on eight patients with asthma.
    Summary · context
    After withholding bronchodilators for 12 hours, patients received either 2 units of intravenous glucagon or 2 ml of saline after a double-blind crossover protocol.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.